

Contract Drug
Product R&D

Complex Injectable Formulations

Clinical Trial Materials

www.ddelabs.com

PHARM R&D CENTER OF EXCELLENCE



- Specialists in injectable drug formulations and combination drug product development
- Injectable solution to complex formulation
 - Immediate to extended-release
 - Small molecule to antibody
- GMP clinical trial material manufacture for early phase clinical development
- Extensive experience in biologics, drug development, device, and delivery systems
- Highly-qualified Ph.D. scientists working in state-of-the-art R&D lab in heart of San Diego



CONTRACTED DRUG PRODUCT R&D



- · Leveraging a deep understanding of molecular properties, formulation, device
 - Integrating delivery system R&D projects into your development program
 - Optimizing target product profile to enhance value proposition











Discovery Support

- Lead molecule profiling
- Clinical candidate evaluation
- Biologic half-life extension

Drug Product Development

- Formulation design
- Drug product development
- Analytical methods

Integration with device

- Device identification
- Formulation compatibility
- Device product development

DDE LABS CAPABILITIES



Pharmaceutical R&D Laboratory

- Formulation, analytical, process, chemistry, device development
- Specialists in complex drug product development
- Peptide and small molecule chemistry, conjugation (e.g., PEGylation)
- Lead candidate selection for peptide and small molecules
- Crystal and salt form selection for small molecules

GMP Fill Finish for Injectable Formulations

- Parenteral facility and quality system approved by the California Department of Public Health Food and Drug Branch
- Clinical trial materials in vials
- QC and stability testing
- Test article for GLP toxicity studies





LEADERS WITH DEEP DOMAIN EXPERIENCE





Lawrence

Chris Rhodes, Ph.D.
VP, Scientific Affairs
Founded Drug Delivery Experts in
2014 after 20 years in biotech and
drug delivery companies in both
technical and executive leadership
roles.



Randall Freund
Director Quality Assurance
Randall has over 40 years experience in the pharmaceutical and medical device industry overseeing Quality and Production groups to implement or improve Quality Management Systems.



D'Souza, Ph.D.
Scientific Director
Discovery,
Chemical and
Process
Development,
Formulation
Organic chemist
with discovery and
early development
experience in small
molecule, peptide,
and protein
synthesis



Laxma Reddy,
Ph.D.
Scientific Director
Formulation and
Process
Development,
Small Molecules
and Biologics
Protein biophysical
chemist with
experience in
extended-release
drug delivery
product
development



Ph.D.
Scientific Director
GMP Operations
and Manufacturing
Over 30 years of
experience in
quality system
regulations, GMP
facility
management,
and product
development

Franco Ferrari,



Becky Bader,
Ph.D.
Associate Director
Formulation for
Pharmaceutical and
Device Applications
Polymer chemistry,
synthesis, and
characterization.
Nanoparticles,
microspheres,
micelles, conjugates
and hydrogels

LEADERS WITH >150 YEARS EXPERIENCE



Our Leaders Have Worked at These Companies





















Protein Polymer













Our Leaders Developed These Products


















OVAPRENE

SUPPORT ACROSS DRUG DEVELOPMENT



LEAD MOLECULE SELECTION

- Peptides
- Small Molecules
- PEGylation
- Salt & Cocrystal Selection

INJECTABLE and LIQUID FORMULATIONS

- Solution in a Vial / Bag
- Lyophilized Powder for Reconstitution
- Suspensions (Aqueous & Oil), Emulsions, Micelles, Liposomes
- Gel-Forming and Particle Systems for Extended Exposure

PRECLINICAL PHASE II PHASE III COMMERCIAL

GMP MANUFACTURING

- Toxicity Test Articles
- Clinical Trial Materials
- QC Release
- Stability Testing

DEVICE INTEGRATION


- Pre-filled Syringe
- Cartridge
- Pen
- Auto-Injector

LIFE-CYCLE MANAGEMENT

- Reformulation
- Long-Acting Systems
- Non-Injectable Delivery (Oral, Nasal, Pulmonary)

MOLECULE AND DELIVERY EXPERIENCE





Small Molecules

- IV, SC, IM
- Nasal
- Oral

Peptides

- SC
- Inhalation
- Nasal
- Ocular
- Oral

Proteins

- SC
- Nasal
- Inhalation

Oligos

• SC

Antibody

• SC

COMPONENTS OF TYPICAL LAB PROJECTS



Lead Molecule Selection



Delivery System Selection



Drug Product Development



Clinical Trial Materials

Analytical Research

Development Assessment

Lead Molecule Design

Molecule Design
Peptide/Protein
Conjugates for Half-Life
Small Molecule

Analytical Development

Preformulation

Delivery System Feasibility

Formulation PK Screening

Delivery System Design
Aqueous or Non-Aqueous Vehicle
Sustained Release Formulation
Triggered or Targeted Systems

Formulation Development

Process
Development
Scale-Up

Analytical Methods Qualification Device Selection & Development

Development Stability

Technology
Transfer
GMP Mfg.

Formulation Process

GMP Fill & Finish

Analytical & QC Release

Stability Testing


Drug Product Design
Pen/Auto-Injector
Pre-Filled Syringe
Nasal/Ocular Drops/Spray

GMP Manufacture
Clinical Trial Materials
QC Release Testing
Stability Studies

EXTENDED-RELEASE INJECTABLE APPROACHES


Illustration of a microsphere dissolving, gradually releasing medicine over time.








EXTENDED-RELEASE INJECTABLE PROGRAMS











Compound Type	MW (kDa)	Injection Frequency	Liposome	Salt	Gel	Microsphere	Suspension
Small Molecule	<1, several	Monthly and longer		V	~	✓	~
Peptide	1	Weekly to Monthly		~	~	~	
Peptide	2	3 to 4 Months		~	~		
Peptide	3, 4	Daily		~			
Peptide	4	Weekly to Monthly		~	~		
Peptide	4, 5	Weekly to Monthly		~	~	~	
Insulin	6	Daily to Weekly	~	~			
Oligonucleotide	8	Daily to Weekly		~			
Oligonucleotide triple combination	10	Daily to Weekly				~	
Protein	15	Weekly		~	~		
Protein	50	Weekly	~		>		
Antibody	150	Weekly to Monthly		V			

FORM SELECTION & PARTICLE SUSPENSION





Free base or acid

Form **Drug Substance:**

Salt or Co-crystal Selection


Or Wet Bead mill

Insoluble Crystal Form <0.01 mg/ml at 37°C PBS Low rate of saturation solubility





Dry Ball mill





Micro-particle Suspension





Nano-particle Suspension

Horizontal oscillatory ball mill for small scale grinding Tube Roller for low energy grinding Vertical planetary ball mill for high energy grinding

STATE-OF-THE-ART DRUG PRODUCT LAB DELIV





DDE LABS DEVELOPMENT CAPABILITIES



Formulation and Process Development

- Homogenizers, emulsifiers
- 37°C incubators for In vitro release testing for extendedrelease injectables (water bath and shake-flask)
- Instron Injection force measurement
- Nano assembler for nanoparticle & liposome
- Shelf–stoppering lyophilizer for cycle development
- Ball mill, tube roller, planetary ball mill for grinding
- Capsule hand-fill for powder and liquid formulations
- Laminar flow hoods for preclinical supply / stability

Chemistry and Chemical Development

- Organic synthesis reactors, jacketed reaction vessels
- Rotary evaporator
- Manifold lyophilizer
- FPLCs for protein purification
- Salt, co-crystal synthesis and form selection
- Prodrug design and synthesis
- Polymer synthesis

Analytical Development

- 15 HPLC (diode array UV Vis, fluorescence, ELSD, RID)
- HPLC MS
- UPLC
- UV/Vis & fluorescence plate readers and nanodrop
- Particle size analyzer (laser diffraction, 1μM 500 μM)
- Dynamic light scattering / zeta potential (1 nm 10 μM)
- Stability Chambers certified and monitored (ICH 25°C/60RH, 40°C/75RH, 2-8°C, -20°C, -80°C)
- Osmometer and Viscometer for characterization
- Endotoxin testing for preclinical / development stability samples
- Scanning electron micrograph
- Visual microscopy

Bioanalytical Development

- MSD ELISA for bioanalysis
- Gel electrophoresis imager for imaging protein gels

PRECLINICAL PARENTERAL FILL EXPERIENCE



Manufactured over 250 stability and preclinical batches in the past 6 years

Batch sizes up to 2 liters historically in process suite

Batch records signed off ahead of fill

Batch release with analytical test results

Concentration, purity, pH, osmolarity, endotoxin, and others

Formulation composition and process methods


- Aqueous and non-aqueous solutions and suspensions
- Liposomes, microspheres, gels, salts, and others

Formulation and development stability manufacturing

- 24 month shelf-life now supporting phase 2 program
- Stability studies to support ANDA filing
- Several development studies for toxicology and clinical formulation selection

GMP FILL FINISH, QC & STABILITY TESTING





Vial Fill and Finish for Clinical Materials

Media fills for 2 ml to 10 ml vials

Fill / Finish Suite (ISO 6) with Hoods (ISO 5)

Gowning Vestibule (ISO 8)

QC Lab for Incoming / Outgoing Materials

GMP Stability Chambers Monitored 24/7



DDE LABS GMP CAPABILITIES



GMP Manufacturing

- ISO 8 Gowning Vestibule
- ISO 6 Process Suite with pass through
- ISO 5 Laminar flow and biosafety cabinet in process suite
- ISO 5 Laminar flow hood in QC lab for compounding
- Depyrogenation oven, autoclave
- Chemical fume hood
- HPLC, osmometer, endotoxin, particle size, pH
- Incubators for environmental monitoring
- Semi-automated filler
- Semi-automated crimper

Formulation and Chemical Process

- Solution formulations
- Gel and viscous formulations
- Homogenization and emulsification
- Microparticle and nanoparticle manufacture
- Salt, prodrug, PEGylation, polymer synthesis

QC Testing and Stability

- HPLC (diode array UV Vis, others as needed)
- Microparticle size by laser diffraction
- Nanoparticle size by dynamic light scattering
- Stability Chambers certified and monitored (ICH 25°C/60RH, 40°C/75RH, 2-8°C, -20°C, -80°C)
- Osmometer and Viscometer
- FTIR for incoming raw material receipt and characterization
- USP particulate testing (HIAC)
- Environmental monitoring
- Endotoxin (Charles River Labs kit)
- Sterility / bioburden outsourced to qualified vendor

Current Media Fills

- 2 ml vials / 1 ml fill volume / 0.5 to 5 liter batch size
- 10 ml vials / 5 ml fill volume / 5 to 10 liter batch size
- Up to 20 to 40 liters batch volume
- Up to 3000 vials per batch


DDE LABS NOW 7 YEARS IN BUSINESS





- 88 DDE Labs clients and 150 lab projects over 7 years laboratory operations
 - 80+ consulting clients since business start 10 years ago
 - 90% of clients in US / remainder EU and JP
 - 15 multinational corporations
- Over the last 3 years (2018 to 2020)
 - 22 DDE Labs clients each year and growing
 - 50% of clients repeat business over 1 to 3 years
 - 80% business from clinical and commercial companies
- GMP sterile fill finish new offering in 2021

DISTRIBUTION OF PROJECT TYPE









PARTNERSHIP OPTIONS



Project Specific Work

- Shorter well-defined projects
- Typically 3 to 9 months
- Time and materials fee-for-service
- Payment milestones

Dedicated R&D Team

- Longer term and broader R&D programs
- Typically 1 to 3 years
- Dedicated resources for program
- Regular quarterly or monthly payments



PARTNER PATENT & PUBLICATION SUPPORT



Veru Healthcare

- Compositions and Methods for Long Term Release of Gonadotropin-Releasing Hormone (GnRH) Antagonists, US 15/885,464
- ASCO presentation on preclinical results

Aileron Therapeutics

Peptidomimetic macrocycles and formulations thereof, US 20160101145 A1

Abvance Therapeutics


 Systems, Compositions, and Methods for Treating Diabetes, Allan Cherrington, Soumitra Ghosh, Christopher A. Rhodes, Jui-Chen Lin, Patent Application US2018016647 filed March 2, 2017

logen LLC

- Emolient topical disinfectants, WO 2018/017645 A1
- "Enhanced topical delivery of non-complexed molecular iodine...", Intl J Pharm 554(2019)81-86

OUR EXPERTISE





Combination Drug Product Development and GMP Manufacturing

- Small molecule through peptide, protein, oligonucleotide, antibody
- Lead molecule profiling and half-life extension
- SC, IM, IV, topical ocular and intraocular formulation design and development
- Extended-release injectable and implantable formulations
- Translation from research through clinical trials and commercialization



WE THRIVE ON SOLVING YOUR MOST CHALLENGING PROBLEMS